Drug Details
BBT-877 is a potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis.
Study Purpose
This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.
